Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P L Darke

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|May 15, 1992
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted designW J Thompson, P M Fitzgerald, M K Holloway, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1988
Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus proteaseR F Nutt, S F Brady, P L Darke, et al.
Journal of Medicinal Chemistry|August 6, 1993
Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligandsA K Ghosh, W J Thompson, M K Holloway, et al.
Biochemical and Biophysical Research Communications|October 14, 1988
HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteinsP L Darke, R F Nutt, S F Brady, et al.
Journal of Medicinal Chemistry|July 20, 1992
A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activityT J Tucker, W C Lumma, L S Payne, et al.
Journal of Medicinal Chemistry|August 16, 1996
Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluationA K Ghosh, J F Kincaid, D E Walters, et al.
Journal of Medicinal Chemistry|September 9, 2000
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitorsB D Dorsey, C McDonough, S L McDaniel, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
Journal of Medicinal Chemistry|May 15, 1992
Synthesis and antiviral activity of a series of HIV-1 protease inhibitors with functionality tethered to the P1 or P1' phenyl substituents: X-ray crystal structure assisted designW J Thompson, P M Fitzgerald, M K Holloway, et al.
Proceedings of the National Academy of Sciences of the United States of America|October 1, 1988
Chemical synthesis and enzymatic activity of a 99-residue peptide with a sequence proposed for the human immunodeficiency virus proteaseR F Nutt, S F Brady, P L Darke, et al.
Journal of Medicinal Chemistry|August 6, 1993
Potent HIV protease inhibitors: the development of tetrahydrofuranylglycines as novel P2-ligands and pyrazine amides as P3-ligandsA K Ghosh, W J Thompson, M K Holloway, et al.
Biochemical and Biophysical Research Communications|October 14, 1988
HIV-1 protease specificity of peptide cleavage is sufficient for processing of gag and pol polyproteinsP L Darke, R F Nutt, S F Brady, et al.
Journal of Medicinal Chemistry|July 20, 1992
A series of potent HIV-1 protease inhibitors containing a hydroxyethyl secondary amine transition state isostere: synthesis, enzyme inhibition, and antiviral activityT J Tucker, W C Lumma, L S Payne, et al.
Journal of Medicinal Chemistry|August 16, 1996
Nonpeptidal P2 ligands for HIV protease inhibitors: structure-based design, synthesis, and biological evaluationA K Ghosh, J F Kincaid, D E Walters, et al.
Journal of Medicinal Chemistry|September 9, 2000
Identification of MK-944a: a second clinical candidate from the hydroxylaminepentanamide isostere series of HIV protease inhibitorsB D Dorsey, C McDonough, S L McDaniel, et al.
Pageof 4